STATEMENT OF NEED/TARGET AUDIENCE

Approximately 40,000 new cases of renal cell cancer (RCC) occur annually, with 13,000 deaths due to the disease. Recently, increased understanding of the biology of RCC and emerging clinical trial results have led to the emergence of new therapeutic options for patients. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. To bridge the gap between research and patient care, Renal Cell Cancer Update utilizes one-on-one interviews and roundtable discussions with leading oncology investigators. By providing access to the latest research developments and expert perspectives, this CME activity assists medical oncologists in the formulation of up-to-date clinical management strategies.

GLOBAL LEARNING OBJECTIVES

• Describe the biology underlying clear cell RCC, including inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene and the pathway leading to VEGF overexpression.
• Examine current treatment options for advanced renal cell carcinoma, including the safety and efficacy of targeted biologic therapies inhibiting VEGF, PDGF and EGF receptors.
• Evaluate the impact of pathologic grade on the selection of therapies and clinical outcomes in RCC and identify molecular targets believed to have clinical relevance in RCC.
• Develop a therapeutic approach for the sequencing and duration of treatment with targeted biologic therapies for the management of RCC.
• Describe ongoing studies in the adjuvant and metastatic settings in order to counsel appropriately selected patients regarding participation.

PURPOSE OF THIS ISSUE OF RENAL CELL CANCER UPDATE

The purpose of Issue 1 of Renal Cell Cancer Update is to support these global objectives by offering the perspectives of Drs Rini, Figlin and Atkins on the integration of emerging clinical research data into the management of renal cell cancer.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 3.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains both audio and print components. To receive credit, the participant should listen to the CDs, review the monograph and complete the Post-test and Evaluation Form located in the back of this monograph or on our website. This monograph contains edited comments, clinical trial schemas, graphics and references that supplement the audio program. RenalCellCancerUpdate.com includes an easy-to-use, interactive version of this monograph with links to relevant full-text articles, abstracts, trial information and other web resources indicated here in blue underlined text.

---

This program is supported by education grants from Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc and Genentech BioOncology.

Home

Interviews
Brian I Rini , MD
- Select publications

Robert A Figlin, MD
- Select publications

MIchael B Atkins , MD
- Select publications

CME Information

Faculty Disclosures

Editor's Office